Novartis seeks to become cancer-drug powerhouse
Novartis AG, seeking to build on the remarkable early success of its cancer drug Gleevec, outlined a pipeline of drug compounds now in clinical development that it hopes will make it an oncology
Novartis AG, seeking to build on the remarkable early success of its cancer drug Gleevec, outlined a pipeline of drug compounds now in clinical development that it hopes will make it an oncology